Zilascorb(2H), a low-toxicity protein synthesis inhibitor that exhibits signs of anticancer activity in malignant melanoma

Anti-Cancer Drugs

Volumn 9, Issue 9, 1998, Pages 797-802

  Semb, K A ^a   Aamdal, S ^a   Mette, E ^a   Ingvar, C ^b   Gullaksen, N ^c   Osmundsen, K ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Pronova AS   (Norway)

Author keywords

Clinical trial; Malignant melanoma; Protein synthesis inhibitor; Zilascorb(2H)

Indexed keywords

BENZALDEHYDE DERIVATIVE; PROTEIN SYNTHESIS INHIBITOR; UNCLASSIFIED DRUG; ZILASCORB(2H); ANTINEOPLASTIC AGENT; ASCORBIC ACID; BENZYLIDENE DERIVATIVE; DRUG DERIVATIVE; ZILASCORB;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG SOLUBILITY; FATIGUE; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; MELANOMA; MOUSE; NAUSEA; NONHUMAN; NUDE MOUSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SELF MEDICATION; TUMOR REGRESSION; VASCULAR ACCESS; VOMITING; XENOGRAFT; DRUG ADMINISTRATION; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; BENZYLIDENE COMPOUNDS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROTEIN SYNTHESIS INHIBITORS;

EID: 0031593440     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199810000-00009     Document Type: Article

References (35)

1. Boyland E. Experiments on the chemotherapy of cancer. Biochem J 1940; 34: 1196-201.
2. Pettersen EO, Dornish JM, Rönning OW. 4,6-Benzylidene-D-glucose, a benzaldehyde derivative that inhibits protein synthesis but not mitosis of NHIK 3025 cells. Cancer Res 1985; 45: 2085-91.
3. Pettersen EO, Nome O, Rönning OW, Oftebro R. Effects of benzaldehyde on survival and cell-cycle kinetics of human cells cultivated in vitro. Eur J Cancer Clin Oncol 1983; 19: 597-614.
4. Pettersen EO, Rönning OW, Nome O, Oftebro R. Effects of benzaldehyde on protein metabolism of human cells cultivated in vitro. Eur J Cancer Clin Oncol 1983; 19: 935-40.
5. Takeuchi S, Kochi M, Sakaguchi K, Nakagawa K, Mizutani T. Benzaldehyde as a carcinostatic principle in figs. Agric Biol Chem 1978; 42: 1449-51.
6. Pettersen EO, Schwarze PE, Dornish JM, Nesland JM. Antitumor effect of benzylidene-glucose (BG) in rats with chemically induced hepatocellular carcinoma. Anticancer Res 1986; 6: 147-52.
7. Sakagami H, Asano K, Fukuchi K, et al. Induction of tumor degeneration by sodium benzylidene ascorbate. Anticancer Res 1991; 11: 1533-8.
8. Kochi M, Majima H, Kanetake C. Phase I and preliminary phase II clinical study of sodium benzylidene ascorbate (SBA). J Cancer Res Clin Oncol 1990; 116: abstr A4.119.32.
9. Kochi M, Takeuchi S, Mizutani T, Mochizuki K, Matsumoto Y, Saito Y. Antitumor activity of benzaldehyde. Cancer Treat Rep 1980; 64: 21-3.
10. Kochi M, Isono N, Niwayama M, Shirakabe K. Antitumor activity of a benzaldehyde derivative. Cancer Treat Rep 1985; 69: 533-7.
11. Kochi M, Ueda S, Hagiwara T. Antitumor activity of sodium benzylideneascorbate. Progr Cancer Res Ther 1988; 35: 338-43.
12. Tanum G, Tveit KM, Host H, Pettersen EO. Benzylideneglucose: no effect after all? Am J Clin Oncol 1990; 13: 161-3.
13. 2H). Br J Cancer 1993; 67: 650-6.
14. 2H). Anticancer Res 1991; 11: 1077-81.
15. Pettersen EO, Larsen RO, Borretzen B, Dornish JM, Oftebro R. Increased effect of benzaldehyde by exchanging the hydrogen in the formyl group with deuterium. Anticancer Res 1991; 11: 369-73.
16. Borretzen B, Larsen RO, Pettersen EO, Dornish JM, Oftebro R. US Patent, October 17 1989; patent number 4,874,780.
17. 1-D-glucose (P-1013). Anti-Cancer Drugs 1995; 6: 456-64.
18. 1-D-glucose (P-1013). Thesis. The Norwegian Radium Hospital 1995.
19. Kuribayashi N, Sakagami H, Sakagami T, et al. Induction of DNA fragmentation in human myelogenous leukemic cell lines by sodium 5,6-benzylidene-L-ascorbate and its related compounds. Anticancer Res 1994; 14: 969-76.
20. Tanuma S, Shiokawa D, Tanimoto Y, et al. Benzylideneascorbate induces apoptosis in L929 tumor cells. Biochem Biophys Res Commun 1993; 194: 29-35.
21. Aoki K, Nakashima H, Hattori T, et al. Sodium benzylideneascorbate induces apoptosis in HIV-replicating U1 cells. FEBS Lett 1994; 351: 105-8.
22. 2H) against ovarian carcinoma, a phase I study. Ann Oncol 1992; 3: abstr 364.
23. 2H) in patients with ovarian cancer. Ann Oncol 1992; 3: abstr 363.
24. Gehan EA. The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961; 13: 346-53
25. 2H), a new reversible protein synthesis inhibitor: a clinical study of an oral preparation. Anti-Cancer Drugs 1997; 8: 296-303.
26. Fodstad O, Kvalheim G, Godal A, et al. Phase I study of the plant protein ricin. Cancer Res 1984; 44: 862-5.
27. Catimel G, Coquard R, Guastalla JP, et al. Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors. Cancer Chemother Pharmacol 1995; 35: 246-8.
28. 2H) on cis-diammine-dichlorplatinum(II)-induced cytotoxicity. Anticancer Res 1992; 12: 33-8.
29. Warrington RC. L-histidinol in experimental cancer chemotherapy: improving the selectivity and efficacy of anticancer drugs, eliminating metastatic disease and reversing the multidrug-resistant phenotype. Biochem Cell Biol 1992; 70: 365-75.
30. Zylicz Z, Hofs HP, Wagener DJT. Potentiation of cisplatin antitumor activity on L1210 leukemia s.c. by sparsomycin and three of its analogues. Cancer Lett 1989; 46: 153-7.
31. Zylicz Z, Wagener DJ, van Rennes H, et al. In vitro modulation of cisplatin cytotoxicity by sparsomycin inhibition of protein synthesis. J Natl Cancer Inst 1987; 78: 701-4.
32. Hofs HP, Wagener DJ, De Vos D, et al. Antitumour activity and retinotoxicity of ethyldeshydroxy-sparsomycin in mice. Eur J Cancer 1995; 31A: 1526-30.
33. Hofs HP, Wagener DJ, De Valk Bakker V, van Rennes H, Ottenheijm HC, de Grip WJ. Concentration and sequence dependent synergism of ethyldeshydroxy-sparsomycin in combination with antitumor agents. Anti-Cancer Drugs 1994; 5: 35-42.
34. Warrington RC, Fang WD. Improved treatment of disseminated B16f10 melanoma in mice with anticancer drugs in combination with L-histidinol. Anticancer Res 1991; 11: 1869-74.
35. Hromas RA, Yung WK. Anguidine potentiates cis-platinum in human brain tumor cells. J Neuro-Oncol 1986; 3: 343-8.